Karyopharm announces investor and analyst event at ash 2022 on selinexor data in patients with treatment-naÏve myelofibrosis

– key opinion leaders to review highlights from updated phase 1 data to be presented at ash 2022 at company sponsored event on monday, december 12 at 8:30 am et – newton, mass. , dec. 5, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a webcast to discuss the updated results from the phase 1 open-label, dose-escalation study evaluating selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis at the 64th american society of hematology (ash) 2022 annual meeting and exposition.
KPTI Ratings Summary
KPTI Quant Ranking